EP 1093464 A2 20010425 - COMPOUNDS, COMPOSITIONS AND METHODS FOR THE ENDOCYTIC PRESENTATION OF IMMUNOSUPPRESSIVE FACTORS
Title (en)
COMPOUNDS, COMPOSITIONS AND METHODS FOR THE ENDOCYTIC PRESENTATION OF IMMUNOSUPPRESSIVE FACTORS
Title (de)
VERBINDUNGEN, ZUSAMMENSETZUNGEN UND VERFAHREN ZUR ENDOZYTISCHEN PRÄSENTATION IMMUNSUPPRESSIVER FAKTOREN
Title (fr)
COMPOSES, COMPOSITIONS ET PROCEDES DESTINES A LA PRESENTATION ENDOCYTIQUE DE FACTEURS IMMUNOSUPPRESSEURS
Publication
Application
Priority
- US 9915225 W 19990706
- US 11112398 A 19980706
Abstract (en)
[origin: WO0001732A2] A fusion protein for the alleviation of symptoms associated with an autoimmune disorder comprising an immunoglobulin or portion thereof linked to one or more autoantigenic polypeptides or fragments thereof, wherein said immunoglobulin or portion thereof is capable of binding to an Fc receptor and being endocytosed by an antigen-presenting cell, and said one or more autoantigenic polypeptides or fragments thereof provides more than one T cell receptor peptide agonist for presentation on the surface of said antigen-presenting cell upon endocytic processing. Said autoantigenic polypeptides may comprise at least a portion of myelin basic protein or at least a portion of proteolipid protein. Method to alleviate symptoms associated with an autoimmune disorder in a patient in need thereof comprising the steps of providing a composition comprising said fusion protein and administering a therapeutically effective amount of said composition to said patient. Autoimmune disorders may include multiple sclerosis, lupus, rheumatoid arthritis, scleroderma, insulin-dependent diabetes and ulcerative colitis. Method for presenting multiple T cell receptor agonists on the surface of a professional or nonprofessional antigen-presenting cell comprising the steps of providing said fusion protein, contacting said fusion protein with at least one Fc receptor present on the surface of a professional or nonprofessional antigen-presenting cell, whereby the fusion protein is internalized by the antigen-presenting cell, and endocytically processing the internalized fusion protein to provide more than one T cell receptor peptide agonist, wherein the provided T cell receptor agonists are presented on the surface of the antigen-presenting cell.
IPC 1-7
IPC 8 full level
C07K 19/00 (2006.01); A61K 39/00 (2006.01); C07K 14/47 (2006.01); C07K 16/00 (2006.01); A61K 38/00 (2006.01)
CPC (source: EP)
C07K 14/4713 (2013.01); C07K 16/00 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/73 (2013.01); C07K 2317/77 (2013.01); C07K 2319/00 (2013.01)
Citation (search report)
See references of WO 0001732A2
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
WO 0001732 A2 20000113; WO 0001732 A3 20000427; AU 5090899 A 20000124; CA 2331771 A1 20000113; EP 1093464 A2 20010425
DOCDB simple family (application)
US 9915225 W 19990706; AU 5090899 A 19990706; CA 2331771 A 19990706; EP 99935427 A 19990706